Cellino is an autonomous, closed loop cell therapy manufacturing company. The company is on a mission to democratize stem cell-based therapies for all eligible patients. Cellino’s next-generation process combines label-free imaging, high-speed laser editing, and artificial intelligence (AI) to automate cell reprogramming, expansion, and differentiation in a closed cassette format. Cellino’s approach enables the parallel processing of thousands of patient samples in a single facility, which is vital for scalable manufacturing
Cell Microsystem delivers solutions for the development of monoclonal colonies from a diversity of cell types focusing on iPSCs. They offer the unique CellRaft® Technology featuring a fully automated, one-platform solution for culturing, phenotyping, and isolating iPSCs in 2D and 3D culture. With the AIR System, users can grow and maintain iPSCs, serial image over time, perform on-array phenotypic and pluripotency assessment, and automatically isolate viable single-cell derived iPSC clones or organoids at multiple time points.
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years’ industry experience, Catalent has the proven expertise, superior technologies and flexible solutions at the right scale to help ensure successful product development, launch, tech transfer and reliable clinical and commercial supply. Our team of +13,500, at +40 sites, helps launch in excess of 200 products every year. We supply more than 73 billion doses of +7,000 products for more than 1,000 customers – or 1 in 20 doses taken by patients globally. We partner with 87 of the top 100 global pharmaceutical marketers, 24 of 25 biological marketers, 21 of 25 leading consumer health marketers, and thousands of small innovators globally. At Catalent, we combine deep expertise in the science of drug development and manufacturing with the art of crafting better treatments to deliver successful medicines for our customers and their patients faster.
At Lonza, we provide contract development, clinical and commercial manufacturing services that enable pharma and biotech companies to bring medicines to patients in need. From the building blocks of life to the final drug product, our solutions are created to simplify your outsourcing experience and provide a reliable outcome when you expect it. Our extensive track record includes commercialization of pioneering therapies and manufacturing of a wide variety of biological and chemical drugs. We continuously invest to solve not just the current, but also the future challenges. Together, let’s bring your next medicine to life.
PBS Biotech, Inc. offers unique single-use bioreactors and contract process development services for the global cell therapy market. Our family of Vertical-Wheel® bioreactors provides optimal and scalable hydrodynamic conditions for human cells such as induced pluripotent stem cells grown as aggregates or mesenchymal stem cells grown on the surface of microcarriers. Our Bioprocess R&D team possesses unparalleled knowledge regarding cell culture process development for a variety of cell types and applications. PBS Biotech is committed to providing scalable solutions for all stages of cell therapy manufacturing, from R&D to clinical studies and ultimately commercial production.
Stem Genomics is a French biotech company specialized in the design of innovative testing technologies for stem cells. Co-founded by Prof. John de Vos and Dr. Said Assou, experts in stem cell genomic integrity, Stem Genomics has emerged from a prestigious scientific environment. The company is a spin-out of the Institute for Regenerative Medicine & Biotherapy (IRMB), located at the heart of the University Hospital Centre of Montpellier. Founded in 2018, we work with +150 clients worldwide, from academic institutions to biotech companies and core facilities.
iOmx Therapeutics is a Munich-based, clinical-stage biopharmaceutical company focused on developing first-in-class cancer immune-therapeutics addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified several proprietary tumor-associated next-generation immune checkpoints and is advancing a pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. The company’s lead program IMT-07 targets SIK3, an immune protective kinase in multiple solid tumors. iOmx is backed by international venture capital investors, such as Wellington Partners, Sofinnova Partners and M Ventures as well as MIG Capital and Athos Biopharma.